Advanced Chemotherapy Technologies

Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial

Retrieved on: 
Thursday, February 11, 2021
Oncology, Medical devices, Health, Other Health, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Oncology, Cancer treatments, Health, Chemotherapy, Occupational safety and health, Advanced Chemotherapy Technologies, Spectrum Financial

Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a Series A investment of $2.5 million with Spectrum Financial.

Key Points: 
  • Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a Series A investment of $2.5 million with Spectrum Financial.
  • This investment is in addition to the previously announced Series A investment of $5.5 million lead by Khosla Venture.
  • Closing additional Series A funding, during these uncertain times, further validates Advanced Chemotherapy Technologies disruptive approach to local drug delivery for treating solid tumors.
  • Advanced Chemotherapy Technologies, Inc. is a privately owned, clinical-stage company developing novel approaches to local drug delivery.

Advanced Chemotherapy Technologies, Inc. Announces $5.5M Series A Financing Round led by Khosla Ventures

Retrieved on: 
Thursday, October 29, 2020
Research, Surgery, Medical devices, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Businesspeople, Khosla Ventures, Corporate governance, Vinod Khosla, Khosla, Advanced Chemotherapy Technologies, Khosla Ventures

Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a $5.5 million Series A investment round led by Khosla Ventures.

Key Points: 
  • Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a $5.5 million Series A investment round led by Khosla Ventures.
  • ACT has made remarkable progress leveraging their seed investment and NIH grants to advance their first product, ACT-IOP-003, into the clinic, said Vinod Khosla, founder of Khosla Ventures.
  • We are excited to have the support of such an outstanding Venture Capital firm in Khosla Ventures, said Tony Voiers, CEO of Advanced Chemotherapy Technologies.
  • Advanced Chemotherapy Technologies, Inc. is a privately owned, clinical-stage company developing novel approaches to local drug delivery.